In the article above [Bond A, Reichert Z, and Stivers JT (2006) Mol Pharmacol 69:547–557], the published version of Fig. 4 contained several clerical errors that are corrected in this erratum. These errors are indicated as follows: (i) panel B was incorrectly assigned to compound 88915 when in fact it is the data for compound 48300; (ii) in panel D, the image for compound 48300 was a duplication of the image shown in panel C for compound 14163; and (iii) the data for compound 88915 were omitted from the original figure. No conclusions were affected by these errors because none of these compounds showed significant inhibition of human topoisomerase I (IC50s > 5 μM), which was the original conclusion obtained from these data. The images shown in revised Fig. 4 were obtained from the same ethidium bromide-stained gel that was shown in the original figure, and these images can be directly traced to the corresponding laboratory notebook entries to confirm that the correct compound labels are being shown.
The revised Figure 4 is shown below:
The authors regret this error and any inconvenience it may have caused.
- Copyright © 2014 The American Society for Pharmacology and Experimental Therapeutics
